clinical trial · NCT05663866
Premedication to Reduce Amivantamab Associated Infusion Related Reactions
Janssen Research & Development, LLC·phase2·active not recruiting·n = 68
Carcinoma, Non-Small-Cell LungDexamethasoneMontelukastMethotrexateAmivantamabLazertinib
brief summary
The purpose of the study is to separately assess the potential of dexamethasone, montelukast and methotrexate administration, prior to amivantamab infusion given through a needle in the vein, to decrease the incidence and/or severity of first-dose infusion related reactions.
started
May 18, 2023
primary completion
Mar 29, 2024
completion
Mar 31, 2027
last updated
Jul 31, 2026
official title
Subcutaneous Methotrexate, Oral Dexamethasone or Oral Montelukast for the Prevention of Infusion Related Reaction Associated With Amivantamab, an EGFR-MET Bispecific Antibody, Among Post-osimertinib Treated EGFRm NSCLC; SKIPPirr, a Phase 2 Study
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol